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ABSTRACT

A radioactive microsphere for radiation therapy o f a
mammal comprising a biologically compatible glass
material containing a beta or gamma emitting radioiso
tope distributed substantially uniformly throughout the
glass. Advantageously, the radioisotope is produced by
irradiation o f the microsphere.
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theless not without its disadvantages. Processing o f
GLASS MICROSPHERES
these ceramic microspheres is complicated because
potentially volatile radioactivity must be added to ce
BAC K G RO UN D OF TH E IN V E N TIO N
ramic melts and the microspheres must be produced and
The present invention relates generally to micro 5 sized while radioactive, with concomitant hazards o f
exposure to personnel and danger o f radioactive con
spheres useful in the treatment o f cancerous and tumor
tamination o f facilities.
bearing tissue and more particularly to novel glass mi
Consequently, a need has remained for a microsphere
crospheres useful in this treatment.
which is useful in the treatment o f cancer or tumor
In the treatment o f patients with certain kinds of
cancer, methods are known in which radioactive parti 10 bearing tissue, but which will not release a radioactive
cles are introduced intravascularly in order to trap the
coating or isotope into remote parts o f the body o f the
radioactive particle at a particular site for its radiation
patient after administration, will not require any techni
effect. According to this technique, a small quantity of
cians to handle any radioactive materials during the
the radioactive particles are injected into the patient
formation and spheroidization o f the microsphere and
and a diffuse, homogeneous field o f radiation within a 15 which have a density which will permit the microselected region o f the body is achieved by permanent
spheres to be suspended in a fluid suitable for injection
lodgement o f the particles in the capillary bed o f the
into a human.
, proposed area, typically the location o f a tumor. In
SUM M ARY OF T H E IN V E N T IO N
early applications o f this technique, yttrium oxide poweer was suspended in a viscous medium prior to ad 20
Among the several objects o f the invention, therefore
ministration. Yttrium was selected for the technique
may be noted the provision o f a novel microsphere for
because o f its suitable characteristics: it emits nearly 100
use in radiation therapy; the provision o f such a micropercent beta radiation. See, e.g., Nolan, et al., Intravas
sphere wherein the radioactive isotope is uniformly
cular Particulate Radioisotope Therapy”, The American
distributed throughout the microsphere material; the
Surgeon 35: 181-188 (1969) and Grady, et. al., Intra-Ar 25
provision o f such a microsphere wherein there is no
terial Radioisotopes to Treat Cancer”, American Sur
significant release o f the radioactive isotope from the
geon 26: 678-684 (1960). This method is not totally
microsphere into the body o f the patient; the provision
satisfactory, however. T w o disadvantages o f yttrium
o f such a microsphere in which the microsphere is com
oxide powder are its high density (5.01 gm /cm 3) and
irregular particle shape. The high density o f pure yt 30 pletely- nonradioactive until irradiated for use in ther
apy; the provision o f such a microsphere which con
trium oxide powder makes it difficult to keep the parti
tains a stable element or isotope that can be activated to
cles in suspension in the liquids used to inject them into
a beta or gamma radiation emitting isotope by neutron
the body, and accelerates their tendency to settle in the
irradiation;
the provision o f such a microsphere which
blood stream prior to reaching the desired tumor. The
sharp comers and edges o f yttrium oxide particles also 35 contains a number o f stable elements or isotopes that
which forms a number o f beta or gamma radiation emit
irritate surrounding tissue in localized areas, and inter
ting isotopes simultaneously during neutron activation,
fere with the uniform distribution o f the radioactive
thereby permitting wide variation in the rate at which
particles in the tumor to be treated.
the radiation is delivered to the body; the provision of
In later applications, the particles used have been
microspheres composed o f an ion exchange resin, or 40 such a microsphere wherein the density o f the sphere is
substantially less than that o f yttrium oxide particles; the
crystalline ceramic core, coated with a radioactive iso
provision o f formulations for treatment o f tumors by
tope such as P-32 or Y-90. Both ion exchange resin and
parenteral administration; and the provision o f pro
crystalline ceramic microspheres offer the advantage o f
cesses for radiation therapy as well as the manufacture
having a density much lower than that o f yttrium oxide
particles, and the ion exchange resin offers the addi 45 o f microspheres o f the present invention.
Briefly, therefore, the present invention is directed to
tional advantage o f being particularly easy to label. See,
novel radioactive microspheres which may be used for
e.g., Zielinski and Kasprzyk, “Synthesis and Quality
radiation therapy o f a mammal. These radioactive mi
Control Testing o f 32 P labelled Ion Exchange Resin
Microspheres for Radiation Therapy o f Hepatic N eo
crospheres comprise a biologically compatible glass
plasms”, Int. J. Appl. Radiat. hot. 34: 1343-1350 (1983). 50 material containing a beta or gamma radiation emitting
However, whenever microsphere comprises a core
radioisotope
distributed
substantially
uniformly
throughout the glass.
material having an external surface coating which con
tains the radioactive isotope there is a risk that the radi
In another aspect, the present invention is directed to
oactive coating may separate from the underlying mi
radioactive microspheres adapted for radiation therapy
crosphere core. A ny mechanical breakage o f the coat 55 o f a mammal. These radioactive microspheres comprise
ing can release unwanted radioactivity to other parts o f
a biologically compatible glass material containing a
the human body which is highly undesirable. Further
beta or gamma radiation emitting radioisotope distrib
disadvantages are presented by the special handling and
uted substantially uniformly throughout the glass. The
precautions that are necessary to coat a radioactive
microsphere is substantially spherical in shape and has a
isotope onto a crystalline ceramic core, or to label ion 60 diameter in the range o f about 5 to about 75 microme
exchange resin.
ters.
In still another application, microspheres have been
Another aspect o f the present invention is directed to
prepared comprising a ceramic material and having a
radioactive microspheres adapted for radiation therapy
radioactive isotope incorporated into the ceramic mate
of a mammal. These radioactive microspheres comprise
rial. While the release o f radioactive isotopes from a 65 a biologically compatible glass material having a radioi
radioactive coating into other parts o f the human body
sotope emitting a therapeutic amount o f beta or gamma
may be eliminated by incorporating the radioisotopes
radiation and a balance o f elements which either do not
into ceramic spheres, the latter product form is never
become radioactive during neutron irradiation or which
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have a half-life that is sufficiently short so that the ele
A still further aspect o f the present invention is di
ment does not emit a significant amount o f beta or
rected to a glass material adapted for radiation therapy
o f a mammal. The glass material comprises between
gamma radiation at the time o f administration.
about 50 and about 70 wt. % silica, between about 1 and
A further aspect o f the present invention is directed
to novel microspheres adapted for radiation therapy o f 5 about 17 wt. % alumina; between about 5 and about 9
wt. % magnesia; and between about 2 and about 10 wt.
a mammal. These microspheres comprise a biologically
% phosphorus pentoxide.
compatible glass having an isotope distributed substan
tially uniformly throughout the glass. These microBRIEF D ESCRIPTIO N OF THE D R A W IN G S
spheres are substantially spherical in shape and the iso
FIG.
1 is a ternary composition diagram o f the yttriatope is selected from the group consisting o f phos- 10
alumina-silica system with a cross-hatched region desig
phorus-32 and yttrium-90 and stable isotopes which are
nating preferred glasses for use in the microspheres of
activatable by neutron irradiation to produce phosthe present invention.
phous-32 or yttrium-90.
FIG. 2 is a series o f plots showing the weight propor
A further aspect o f the present invention is directed
to novel glass microspheres adapted for radiation ther- 15 tion o f elemental phosphorus leached from various mi
crospheres o f the invention as a function o f time o f
apy o f a mammal. These glass microspheres comprise
exposure to deionized water at 50° C.
silica, alumina and yttria and have a diameter o f less
FIG. 3 is a plot similar to FIG. 2 showing leaching of
than about 75 micrometers.
radioactive
phosphorus from microspheres exposed to
A still further aspect o f the present invention is di
rected to a method o f preparing a microsphere for use in 20 human blood plasma at 37° C.
FIG. 4 is a plot o f solution activity o f Y-90 divided by
a radiation therapy procedure. The method comprises
initial Y-90 activity versus time for a YAS glass sample
irradiating a microsphere comprising a glass material
evaluated in Example 2.
containing a stable element or isotope and thereby acti
FIG. 5 is a plot o f decay o f leachate from a YAS glass
vating the element or isotope to a beta or gamma radia
sample versus time containing the results o f Example 2.
tion emitting isotope.
A still further aspect o f the present invention is di
D ESCRIPTIO N OF TH E PREFER R ED
rected to a method o f radiation therapy for a mammal.
EM BO DIM ENT
This method comprises administering to the mammal,
In accordance with the present invention, novel mi
glass microspheres containing a beta or gamma radia- 3Q
crospheres have been devised for use in the therapy of
tion emitting radioisotope distributed substantially uni
certain cancers and tumor bearing tissue. These novel
formly throughout the glass.
microspheres comprise a glass material having a stable
A further aspect o f the present invention is directed
element which can be activated by neutron irradiation
to novel microspheres adapted for irradiation and subse
to produce a beta or gamma radiation emitting isotope
quent use in radiation therapy o f a mammal. The micro- 35
distributed substantially uniformly throughout the
spheres comprise a glass material containing phospho
glass. Thus, these novel microspheres may be manufac
rus or yttrium distributed substantially uniformly
tured and sized before radioactivity is induced, thereby
throughout the glass and a balance o f elements selected
avoiding the necessity o f either adsorbing a radioele
from the group consisting o f those elements which ei
ment onto the microsphere surface, or adding radioele
ther do not become radioactive during neutron irradia- 40 ments to a high temperature melt and spheroidizing and
tion or which have a half-life that is sufficiently short so
sizing the particles while intensely radioactive.
that the element does not emit a significant amount of
Various biologically compatible glasses may be used
beta or gamma radiation at the time o f administration.
in preparing the microspheres o f the present invention.
A further aspect o f the present invention is directed
Preferably, these glasses are good solvents for small
to novel microspheres adapted for radiation therapy o f 45 amounts o f nearly all oxides and have sufficient chemi
a mammal. These microspheres comprise a glass mate
cal durability so that, after the microspheres are admirial containing an element distributed substantially uni
nisted to a target portion o f the patient’s body, no signif
formly throughout the glass and which, upon being
icant amount o f any radioactive isotope is lost from the
subjected to an effective amount o f neutron irradiation,
patient’s body or transformed to other parts o f the pa
emits a therapeutic intensity and amount o f beta or 50 tient’s system. It is further preferred that the glasses do
gamma radiation. The balance o f elements contained by
not incorporate any elements that may cause the micro
the microsphere are selected from the group consisting
sphere to emit any significant amount o f undesired radi
o f carbon, nitrogen, oxygen, fluorine, sodium, magne
ation. In accordance with a preferred embodiment o f
sium, aluminum, silicon, potassium, vanadium, manga
the present invention, many aluminosilicate glasses and
nese, gallium, niobium, iodine, lead, titanium, copper, 55 lead silicate glasses have been found to be good solvents
germanium, and zirconium.
for small amounts o f nearly all oxides, thereby permit
A still further aspect o f the present invention is di
ting great versatility: the dose and profile o f the radia
rected to a radioactive glass material adapted for radia
tion emitted by microsphere may be controlled by in
tion therapy o f a mammal. The glass material comprises
corporating elements having the desired emission chaan yttrium oxide-aluminosilicate glass having a compo- 60 rateristics after irradiation. Many aluminosilicate and
sition lying substantially within a quadrilateral region o f
lead silicate glasses also have sufficient chemical dura
the ternary composition diagram o f the yttria-aluminability to prevent the loss o f a significant amount o f the
silica system. This quadrilateral region o f the ternary
radioactive isotope into the patient’s system after the
diagram is defined by its four corners having the follow 
microsphere is administered, yet do not need to contain
ing combination o f weight proportions o f the compo- 65 any elements that may cause the microsphere to emit a
nents: 20% silica, 10% alumina, 70% yttria; 70% silica,
significant amount o f undesired radiation. Various alu
10% alumina, 20% yttria; 70% silica, 20% alumina,
minosilicate glasses and lead silicate glasses thus may be
10% yttria; and 20% silica, 45% alumina, 35% yttria.
used in accordance with a preferred embodiment o f the
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present invention. For instance, preferred glasses incor
tively short period o f time, e.g., on the order o f about 1
porating yttrium are yttrium oxide-aluminosilicate
week or less. Elements such as yttrium and phosphorus
(YAS) glass compositions lying substantially within a
which form radioisotopes having a half-life greater than
quadrilateral region o f the ternary composition diagram
about tw o days and less than about 30 days are particu
o f the yttria-alumina-silica system, the quadrilateral 5 larly preferred as the elements which emit therapeutic
region being defined by the four corners having the
radiation. The balance o f the constituent elements o f the
following specified weight proportions o f each o f the
glass are preferably selected so that when administered,
components:
the microsphere does not emit any significant amount of
radiation other than that emitted by Y-90 or P-32. This
result may be accomplished by selecting a glass compo
S i0 2
AI2O 3
Y 2O 3
sition that contains yttrium-89 or phosphorus-31 and a
20%
10%
70%
balance o f elements which either do not become radio
70%
10%
20%
active during neutron irradiation or which have a suffi
70%
20%
10%
ciently short half-life so as not to emit a significant
20%
45%
35%
amount o f beta or gamma radiation at the time o f admin
istration. Elements which either do not become radioac
This quadrilateral region is shown in FIG. 1. The den
tive during neutron irradiation or which have a suffi
sity o f the YAS glasses is preferably within the range of
ciently short half-life so as not to emit a significant
about 2.7 to about 3.9 grams/cc. By way o f further
amount o f beta or gamma radiation are listed in Table I
example, preferred glasses incorporating phosphorus 20
without an asterisk; those marked with an asterisk in
comprise silica, alumina, magnesia and phosphorus con
Table I may form small amounts o f unwanted radioac
taining between about 50 and about 70 wt. % silica,
tive isotopes.
__________ TAB L E I_______________________________
EL EM EN TS H A V IN G A C C EPTA B LE N U CLEA R PRO PERTIES
FO R U SE If [ R A D IO TH ER A PE U TIC G LASS M ICROSPHERES

Na
K
—

Mg
—
—

—
— Ti*
— Zr*

between about 1 and about 17 wt. % alumina, between
about 5 and about 9 wt. % magnesia and between about
2 and about 10 wt. % phosphorus pentoxide. The den
sity o f the glasses incorporating phosphorus is preferably within the range o f about 2.2 to about 2.7 grams/cc.
The microspheres o f the present invention may com 
prise essentially void-free glass microspheres, micro
shells, i.e., microspheres having a hollow core or glass
microspheres having a “foam-like” structure where the
microsphere has a plurality o f hollow cells. Microshells
and microspheres having a plurality o f hollow cells may
be preferred where it is desired to employ a microsphere having a density substantially less than that of
the essentially void-free microsphere.
Whether the microspheres o f the present invention
are essentially void-free, microshells, or have a plurality
o f hollow cells, it is preferred that the microspheres be
substantially spherical, i.e., there are no sharp edges or
points that would cause the microsphere to lodge in a
location other than that desired. In this context, elipsoidal and other similarly shaped particles that do not have
sharp edges or points would be considered to be sub
stantially spherical in shape.
In a preferred embodiment o f the present invention,
the constituent elements o f the microspheres are chosen
so that when administered to the patient, the micro
spheres emit a therapeutic intensity and amount of
short-range (e.g., a penetration o f the tissue on the order
o f about several millimeters or less) beta or gamma
radiation but will not emit a significant amount o f un
wanted beta or gamma radiation which could have a
negative impact on healthy tissue surrounding the can
cerous or tumor bearing tissue. In this regard, it is pre
ferred that the constituent elements o f the glass be selected so that the therapeutic radiation emitting radio
isotopes are the only constituent isotopes which may
emit a significant amount o f radiation beyond a rela-

V
—
Nb
—

Mn

—

— —Cu*

A1
— Ga

—

—

— — —

---------- Pb

c

n

o

F —

Si
Ge*

—
—

—
_

— —
_ _

In accordance with the present invention, the constit
35 uent elements o f the glass may be chosen so that the
radiation may be tailored to deliver a radiation profile
that is ideally suited for a particular treatment. For
instance, in some instances it may be preferred to em
ploy a radiotherapeutic product with short-lived beta
40 emitter Y-90, while in others it may be preferred to
utilize the longer-lived beta emitter P-32 or a product
that has both components. In other instances, it may be
desirable to employ a radiotherapeutic product with a
gamma emitting isotope or a mixture o f beta and gamma
45 emitting isotopes. The microspheres o f the present in
vention permit this versatility: a combination o f ele
ments having the desired radiation emission profile may
be incorporated into the glass material. In a preferred
embodiment, a beta emitter and/or a low energy
50 gamma emitting nuclide is incorporated into the microspheres. In a most preferred embodiment, yttrium and
/o r phosphorus are incorporated into the microspheres;
P-32 emits pure beta radiation and Y-90 emits nearly
pure beta radiation which will spare healthy tissue re
55 mote from the tumor site in which the microsphere is
embedded.
The constituent elements o f the microspheres o f the
present invention are also preferably chosen so that the
microsphere does not contain any significant amount o f
60 elements which have a large cross-section for neutrons:
A n example o f one such element that has a large crosssection for neutrons is boron which has a cross-section
o f 3837 barns. In a most preferred embodiment, the
microspheres do not contain a significant amount o f any
65 elements that have a cross-section for neutrons greater
than about 200 bams.
The radiation dosage delivered through the use o f the
activated microspheres upon administration to the pa
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tient can be varied by controlling the number o f micro
spheres administered and by controlling the amount of
radiation emitting isotopes contained by the microspheres. The amount of radiation emitting isotopes con
tained by the microspheres is affected by tw o factors: 5
the amount o f the stable element that will be converted
to a radioelement by irradiation, and the length of time
o f irradiation. Preferably, the microspheres are irradi
ated for a short period o f time with an intense thermal
neutron flux generated by a nuclear fission reactor in 10
stead o f being irradiated for a significantly longer per
iod o f time with a lesser neutron flux. This technique of
a short, intense irradiation o f the microsphere is particu
larly preferred where one or more o f the constituent
elements o f the microsphere has an undesired radiation 15
profile and a half-life that is significantly greater than
those constituent elements having a desired radiation
profile. Thus, the manner o f irradiation may be con
trolled in such a manner to impart the microsphere with
a therapeutic intensity and amount o f radiation while 20
also minimizing the amount o f undesired radiation.
The microspheres o f the present invention may be
processed to have a size that is appropriate for the ther
apeutic application. The characteristics o f the tissue in
which the microspheres will be embedded generally 25
dictate the appropriate size o f the microspheres to be
employed. Generally, microspheres having a size some
where within the range o f about 5 to about 75 microme
ters are employed for therapeutic applications and in
many cases it is preferred that the microspheres have a 30
size somewhere within the range o f about 5 to about 50
micrometers. For instance, in the treatment o f liver
cancer, it is preferred to employ microspheres having a
size substantially within the range o f about 20 to about
30 micrometers; microspheres o f this size are small 35
enough to be conveniently delivered to the liver
through the hepatic artery but are too large to pass
through the capillary bed o f the liver.
The microspheres may be administered to the patient
through the use o f catheters either alone or in combina 40
tion with vasoconstricting agents or by any other means
o f administration that effectively causes the micro
spheres to become embedded in the cancerous or tumor
bearing tissue. For purposes o f administration, the mi
crospheres are preferably suspended in a medium that 45
has a sufficient density or viscosity that prevents the
microspheres from settling out o f suspension during the
administration procedure. Presently preferred liquid
vehicles for suspension o f the microspheres include
polyvinylpyrrolidone (PVP), sold under the trade des 50
ignation Plasdone K-30 and Povidone by G A F Corp, a
contrast media sold under the trade designation Metrizamide by Nyegard & Co. o f Oslo, Norway, a contrast
media sold under the trade designation Renografin 76
by E. R. Squibb & Co., 50% dextrose solutions and 55
saline.
The microspheres o f the present invention may be
prepared from a homognous mixture o f powders (i.e.,
the batch) that is melted to form the desired glass com
position. The exact chemical compounds or raw materi 60
als used for the batch is not critical so long as they
provide the necessary oxides in the correct proportion
for the melt composition being prepared. For instance,
if a YAS glass is being made, then yttria, alumina, and
silica powders could be used as the batch raw materials. 65
The purity o f each raw material is preferably greater
than 99.9%. After either dry or wet mixing o f the pow 
ders to achieve a homogeneous mixture, the mixture
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may be placed in a platinum crucible for melting. High
purity alumina crucibles can also be used if at least small
amounts o f alumina can be tolerated in the glass being
made. The crucibles containing the powdered batch are
then placed in an electric furnace which is heated 1500°
to 1600° C., depending upon the composition. In this
temperature range, the batch melts to form a liquid
which is stirred several times to improve its chemical
homogeneity. The melt should remain at 1500° to 1600°
C. till all solid material in the batch is totally dissolved,
usually 2-5 hours being sufficient. When melting and
stirring is complete, the crucible is removed from the
furnace and the melt is quickly quenched to a glass by
pouring the melt onto a cold steel plate or into clean
water. This procedure breaks the glass into fragments,
which aids and simplifies crushing the glass to a fine
powder. The powder is then sized and spheroidized for
use.
Where it is desired to use microspheres having a
diameter in the range o f about 20 to about 30 microme
ters as for example in the treatment o f liver cancer, it is
preferred that the quenched and broken glass be first
crushed to about minus 100 mesh particles using a mor
tar and pestle. The minus 100 mesh material is then
ground using a mechanized mortar and pestle or ball
mill, until it passes a 400 mesh sieve. The particles are
formed into glass microspheres by introducing the
—400 mesh particles into a gas/oxygen flame where
they are melted and a spherical liquid droplet is formed
by surface tension. The droplets are rapidly cooled
before they touch any solid object so that, their spheri
cal shape is retained in the solid product.
Just prior to spheroidizing, the —400 mesh powder is
rescreened through a 400 mesh sieve to destroy any
large agglomerates that may have formed during stor
age. The —400 mesh powder is then placed in a vibra
tory feeder located above the gas/oxygen burner. The
powder is slowly vibrated into a vertical glass tube
which guides the falling powder particles directly into
the hot flame o f a gas/oxygen burner. Any burner capa
ble o f melting —400 mesh particles o f the particular
glass composition being used is satisfactory. A typical
rate for feeding the powder to the flame is 5 to 25 gm /hr
with the described apparatus. The flame o f the burner is
directed into a metal container which catches the small
glass beads as they are expelled from the flame. This
container can be made o f any metal which can with
stand the heat o f the burner and does not contaminate
the glass. The container needs to be large enough so
that the molten spheres can cool and become rigid be
fore hitting any solid surface o f the catcher container.
After spheroidization, the glass spheres are collected
and rescreened. When the microspheres are intended to
be used in the treatment o f liver cancer, the fraction less
than 30 and greater than 20 micrometers in diameter is
recovered since this is the desirable size for use in the
human liver. After screening, the —3 0 /+ 2 0 microspheres are examined with an optical microscope and
are then washed with a weak acid (HC1, for example),
filtered, and washed several times with reagent grade
acetone. The washed spheres are then heated in a fur
nace in air to 500°-600° C. for 2 -6 hours to destroy any
organic material.
The final step is to examine a representative sample of
the —3 0 /+ 2 0 spheres in a scanning electron micro
scope to evaluate the size range and shape o f the
spheres. The quantity o f undersize spheres (less than 10
micrometers in diameter) is determined along with the

9
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concentration o f non-spherical particles. The composi
tion o f the spheres can be checked by energy dispersive
x-ray analysis to confirm that the composition is correct
and that there is an absence o f chemical contamination.
The glass microspheres are then ready for irradiation 5
and subsequent administration to the patient.
In accordance with the present invention, the above
processing steps are merely exemplary and do not in
any way limit the present invention. For instance, those
skilled in the art will appreciate the steps involved in 10
producing a microshell or a microsphere having a plu
rality o f hollow cells. Similarly, the present inventon is
not limited to glass microspheres having a size de
scribed above; the size o f the microspheres o f the pres
ent invention may be varied according to the applica 15
tion.
In accordance with a preferred embodiment, the
microspheres o f the present invention may be advanta
geously used in the treatment o f liver cancer. For this
purpose, it is presently preferred to use essentially void- 20
free YAS glass microspheres having a composition
lying within the previously identified quadrilateral re
gion o f the yttria alumina-silica composition diagram
and that have an activity o f about 0.2 to about 0.6
C i/gm o f glass after irradiation. To achieve the desired 25
level o f activity, the Y AS microspheres are irradiated
for an effective period. For instance, Y A S microspheres
comprising about 40% by weight yttria are irradiated in
a nuclear reactor to a level o f about 3 C i/gm which
requires about 75 hours o f irradiation at 1X 1014 neu- 30
trons/cm2sec. Thus, by activating the microspheres to a
level above the preferred administration range, decay o f
activity o f the activated microspheres may occur during
processing and shipment prior to administration to the
patient and still permit administration within the pre 35
ferred range o f activity. If microshells or microspheres
comprising a plurality o f hollow cells are used instead
o f solid microspheres, the specific activity after irradia
tion needs to be higher in order to account for the de
crease in mass o f similarly sized spheres. If it were pre 40
ferred to use a glass microsphere containing P-32 in
stead o f Y-90 for the treatment o f liver cancer, the spe
cific activity required through irradiation may be con
siderably lower than that required for Y-90 microspheres; P-32 has a longer half-life than Y-90 (14.3 days 45
vs. 64 hours for Y-90) which results in less decay during
transit and which causes it to remain active in the body
longer than Y-90.
The microspheres o f the present invention may be
used in the treatment o f liver cancer by introducing a 50
catheter into the hepatic artery and administering the
radioactive microspheres. Preferably, the microspheres
are suspended in a medium such as Plasdone K-30 or
Metrizamide for purposes o f administration. The parti
cle density in the liver after administration is preferably 55
on the order o f about 4000 microspheres per gram o f
liver. When administered in this manner, the micro
spheres become embedded in the capillary bed o f the
tumorous liver tissue rather than in normal liver,
thereby delivering the radiation dosage primarily to the 60
tumor. Vasoconstricting drugs may additionally be used
to decrease hepatic artery flow to normal liver. Micro
spheres used in this treatment preferably comprise ei
ther P-32 or Y-90 because o f their short-ranged radia
tion.
65
Other cancerous or tumor bearing tissue may simi
larly be treated with the microspheres o f the present
invention. Depending upon the application, it may be
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desirable to incorporate a gamma emitting radioisotope
or a combination o f gamma and beta emitting radioiso
topes into the microsphere. Alternatively, a physical
mixture o f microspheres having different radiation pro
files may be used in order to tailor the treatment for a
particular case. For instance, the treatment may com 
prise administration o f a physical mixture o f two differ
ent microspheres, the first type containing Y-90 and the
second type containing P-32.
The following examples illustrate the invention.
EX A M PLE 1
A. M ICROSPHERE PREPAR ATIO N
The glass compositions listed in Table II were pre
pared from reagent grade chemicals. Batches yielding
50 grams o f glass were melted in platinum crucibles in
an electric furnace at the approximate temperatures in
Table II. A typical melting cycle required three hours
for batch additions at 1000° C. and three to four hours
to refine the melt at the approximate melting tempera
ture. The crucible containing the melt was quenched in
25° C. water, after which the resultant glass frit was
broken from the crucible and ground to —100 mesh.
The —100 mesh glass powder was then slowly fed by a
vibrating spatula into an oxygen/propane flame where
surface tension pulled the molten particles into spheres.
The flow rates o f oxygen and propane were adjusted for
each glass composition so as to yield the highest frac
tion o f spherical particles. After spheroidizing, the mi
crospheres were w et screened with deionized water,
rinsed in acetone and dried.
B. CHEM ICAL D U R A BILITY M EASU REM ENTS
The compositions marked with an asterisk in Table II
were immersed in deionized water at 50° C. and the
release o f elemental phosphorus measured as a function
o f time. Samples o f 76 to 150 fxm diameter micro
spheres, each sample weighing 0.5 gm, were placed in
high density polyethylene bottles with 25 ml o f deion
ized water. The bottles were then placed in an oven at
50° C .± 5 ° C. for 7, 15, 30, and 40 days with brisk agita
tion for 5 seconds on days 2 and 27. After removing a
sample from the oven, the aqueous phase was filtered
through Whatman # 5 2 filter paper. Each filtrate was
then fumed with Perchloric acid (70-72%) at 75° C. to
remove any soluble silica that might interfere with the
spectrophotometric determination o f phosphorus. In
the determination o f phosphorus, the fumed solutions
were mixed with an acidic ammonium vanadate, ammo
nium molybdate reagent to form a yellow vanadomolybdate-phosphoric acid complexs. The concentration
o f phosphorus was calculated from the absorbence of
the solution measured at 400 nm.
C.
SPECTROPHOTOM ETRIC
D E T E R M IN A 
TION OF PHOSPHORUS
Samples o f 25 ml deionized water in w hich 0.5 gm of
microspheres had been immersed at 50° C. for 7, 15, 30,
and 40 days were prepared for determination o f phos
phorus content. Standardized solutions o f known phos
phorus ppm were prepared and their absorbence mea
surements at 400 nm. plotted. From this standardization
curve, the measured absorbence values at 400 nm. from
the sample specimens were converted to ppm phospho
rus concentrations. These values were then multiplied
by dilution factors and converted to the w eight o f phos
phorus confirmed in the sample specimens, shown in
Table V . Division by the weight o f phosphorus in the
known initial weight o f glass yields the w t % o f phos
phorus leached given in Table V.

11
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The calibration curve becomes non-linear at very low
concentrations. This uncertainty in using the calibration
line to calculate the phosphorus ppm in solution in
creases with decreasing phosphorus concentration. One
ppm standard solutions are 4% in error by the time
absorbence measurements are converted back to ppm
values from the calibration curve. This error reaches
6% for 0.5 ppm phosphorus standard solutions. Testing
standards o f 0.1 ppm phosphorus and converting ab
sorbence values back to ppm values by the calibration
curve yields errors up to 22%. Since all solutions tested
had calculated concentrations o f phosphorus greater
than 0.168 ppm, it is safe to assume the maximum error
in the wt % phosphorus leached values to be less than
22%. The error in values decreases as the concentration
o f phosphorus in the test specimen increases.
D . COMPOSITIONAL OVERVIEW
The glass compositions evaluated in this example can
be generally classified as either a modified soda-lime
silica or a magnesium aluminosilicate. In the soda-lime
compositions, the lime was eliminated so as to preclude
the formation o f unwanted 45Ca, and replaced with
magnesium and/or potassium. Alumina was added to
nearly all the compositions (see Table II), to improve
the chemical durability. Compositions UMR-17 and
UMR-25 contain zirconia, which significantly improves
the resistance o f other silicate glasses to alkaline attack.
Manganese dioxide was added to UMR-24 also to im
prove the resistance to alkaline attack.
In attempts to reduce the melting temperatures and
viscosity, and to keep the alkali content low , lead oxide
was included in a number o f batches, and the magne
sium carbonate in the batch was replaced by magnesium
fluoride. The fluxing ability o f the lead oxide additions
appeared minimal at levels less than 10 w t %. Higher
additions caused phase separation. The substitution of
magnesium fluoride for magnesium carbonate during
batching showed a slight improvement in lowering the
melt viscosity.
E. SPHERQ IDIZATIO N
In composition UMR-24 large bubbles developed in
some o f the microspheres during spheroidization. Dur
ing subsequent w et screening, the hollow microspheres
could easily be separated from the solid spheres by
floating the hollow spheres away from the heavier solid
spheres. The formation o f bubbles in glass microspheres
is o f interest as a means o f lowering the bulk density o f
the microspheres. Table III lists the density o f currently
used essentially void-free microspheres, and the mea
sured values for the seven glass compositions evaluated
in the chemical durability tests. The higher density of
glass microspheres requires a suspending solution with
either a higher viscosity or higher density to prevent
settling o f the microspheres prior to their use.
F. STRAY R A D IA T IO N TESTIN G
The compositions evaluated for chemical durability
were also studied after neutron irradiation to check for
the emission o f undesired radiation and a low , tolerable
backround o f undesireable radiation was found in al
most all compositions. Only UMR-17 contained a signif
icant amount o f an unwanted radioactive isotope and
may not be considered acceptable for use in the treat
ment o f liver cancer. The unwanted radioactive isotope,
95Zr, formed from the 12 wt % zirconia in the glass. By
reducing the zirconia to 4 w t %, the unwanted radiation
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was lowered to such a level that UMR-26 is acceptable
for this application based on this evaluation.
G. CHEM ICAL D U R A BILITY T EST IN G
Results from the elemental phosphorus leaching test
are shown in FIG. 2. The wt % phosphorus leached
was calculated from the weight o f phosphorus found in
solution, divided by the initial weight o f phosphorus in
the microspheres. The decrease in phosphorus release
between glasses UMR-3 and UMR-10 is attributed to
changing the alkali from sodium to potassium, and to
the reduction in the total alkali content o f the glass with
a corresponding increase in the silica content. The re
maining compositions are closely grouped with the high
zirconia containing glass, UMR-17, and the magnesium
alumino silicate, UMR-21, showing the lowest phos
phorus releases.
Any chemical corrosion o f the glass microspheres by
deionized water is expected to change the solution pH.
To a limited extent the change in pH should be propor
tional to the degree o f chemical reaction. The pH values
o f the solution after 74 days at 50° C. is given in Table
IV. The higher pH values indicate UMR-3 and UMR25 have significantly reacted with the water relative to
the other compositions.
In the second durability test, the release o f radioac
tive 32P was measured for the same glasses used in the
first durability test. In this test, microspheres 46 to 75
fim in diameter were first rinsed in 0.12 N HC1 at room
temperature, rinsed in deionized water and then neutron
irradiated. After irradiation, the microspheres were
again rinsed in 0.12 N HC1, rinsed in deionized water
and transferred to vials containing 10 ml o f human
blood plasma at 37° C. Samples o f human blood plasma
(1.1 ml), were removed from the vials periodically and
their beta radioactivity measured with a liquid scintilla
tion counter. The activity o f subsequent samples was
corrected for the decreasing volume o f plasma in the
vial. In FIG. 3, the percent radioactive phosphorus
leached is the radioactivity o f phosphorus in solution
divided by the decaying total o f radioactive phosphorus
in the glass.
Comparison o f the phosphorus leaching data in
FIGS. 1 and 2 show a good correlation in the relative
ranking o f glasses evaluated. The combined information
gathered in the first durability test and pH testing is
representative o f how compositions performed in the
second test, thus these methods can be used to accu
rately screen future compositions without handling
radioactive samples.
To determine the suitability o f glasses based on their
release o f radioactive phosphorus, a maximum value of
0.1% radioactive phosphorus leached after 30 days was
arbitrarily established. This value represents the esti
mated maximum extent o f leaching from a 5% by
weight phosphorus pentoxide glass which will produce
radioactive P-32 level below the maximum level which
a healthy adult can tolerate in his body without adverse
effect.
In FIG. 3, three compositions satisfy the adopted
value o f 0.1% radioactive phosphorus leached after 30
days; they are UMR-21, UMR-17, and UMR-26. As
previously noted, UMR-17 has undesireable radioactive
emissions that make it unacceptable for this application.
UMR-21 is a magnesium alumina silicate composition
which had the lowest release o f phosphorus in both
leaching tests.
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__________ TAB L E II__________

G LASS COM POSITIONS PR EPA R E D
_____________________Batch Composition (wt %) ______________________ Approx. Melting
PbO
S i0 2 a i 2o 3
Na20
K 20
Other
P 2O 5
Temp. (°C.)

SamPle
Identification

Spheres
Observations

Produced

MgO
UMR-l
UMR-2
•UMR-3
UMR-4
UMR-5
UMR -6
UMR-7
UMR -8
UMR-9
•UMR-10
UM R-l 1
UMR-12
UM R-l 3
UMR-l 4
UM R-l 5
UMR-16
•UMR-17
UM R-l 8
UM R-l 9
UMR-20
•UM R-21
UMR-22
UMR-23
•UMR-24
•UMR-25
•UMR-26

72
70.6
69.2

3
2.9
2.9

66.6

2.8
1

72
72
72
74
68.5
73.1
1.5
35
35
60
70
66
68
55.8
52.0

3
3
1
2
1
1
27.2
17.6

53.3
65.2
61.4
66.2
61.4
61.4

14.9
2.7
2.7
2.8
2.7
2.7

3

1
1
2.9
2.1

10

15
14.7
14.4
13.9
15

9.8
9.6
9.3

10
10
10
8

5
9
9

4.5
4.5
4.5
4.6
4.5
4.5

1550
1550
1525
1550
1525
1550

pours
pours
pours
pours
pours
pours

yes
yes
yes
yes
yes
yes

2(Y20 3)

10

4.8
5.4
5

7
7
5
12
9
7

4

12
20.4
22.1
M gF,
27.3
14.0
14.0
9.7
14.0
14.0

10
77.9

yes
yes
ves
yes
yes
no
no
no
yes
yes
no
no
y es+
no
yes+
yes-lyes 4yes
yes
no

15
15
5
14.3
10.8

9.5
8.6
93.5
55
50
22
7
10
3

pours very slow
pours very slow
pours slow
pours slow
pours slow
did not melt
did not melt
did not melt
pours very slow
unable to pour
crucible leaked
pours easy
phase separated
not homogeneous
pours slow
unable to pour
unable to pour
unable to pour
pours slow
pours easy

3.9
7.4

2
4

1550
1550
1525
1500
1500
1550
1550
1550
1550
1550
1000
1350
1400
1500
1500
1500
1550
1525
1550
1300

2.0

5

5
5
5
5

13.6
13.6
13.8
13.6
13.6

3.8
3.8

2(Y20 3)

12(Zr02)

2.9(M n02)
3.8(Zr02)

slow
slow
slow
very slow
slow
very slow

•Compositions evaluated for chemical durability.
+ Black and white microspheres, possible reduction of lead during spheridization.

T A B L E III

T A B L E V-continued

D EN SITY O F TY PIC A L M IC RO SPH ERE
M ATER IA LS AN D SE LE C T ED G LA SS SAM PLES
Density
Material
Sample
(g/cm 3)
Plastic
Ceramic*
Glass

(Polystyrene)
(bulk density)
UMR-3
UMR-10
UMR-17
UMR-21
UMR-24
UMR-25
UMR-26

1.05
2.00
2.41
2.35
2.56
2.55
2.37
2.38
2.37

W T % EL EM EN T A L PHOSPHORUS LE A C H IN G D A TA
W t of
Absorb
Phosphorus (me)
Wt %
Sample
Time
ence at
Calculated
Initially
Phosphorus
ID
400 nm
(days)
in Solution in Glass
Leached

40 UMR-10

UMR-17

*3M Co., St. Paul, MN

45
UMR-20
UM R-21

TAB L E IV
PH O F D E IO N IZ E D W A TER
IN C O N TA CT W ITH G LASS M ICRO SPH ERES
A FT E R 74 DAYS A T 50" C.
Sample
pH
W ater Blank
UMR-17
UMR-10
UMR-21
UMR-26
UMR-24
UMR-25
UMR-3

4.70
7.30
7.30
7.30
7.45
7.90
8.95
9.50

50

UMR-24

UMR-25

(7.40)*
(7.60)*

55

(8.00)*
(8.95)*
(9.50)*

UMR-26

•Duplicate sample
^

TABLE V

30
40
7
15
30
40
7
15
30
40
8
7
15
30
40
7
15
30
40
7
15
30
40
7
15
30
40

0.079
0.095
0.017 +
0.016+
0.050
0.042
0.018
0.014
0.020
0.024
0.694*
0.013
0.014
0.021
0.017
0.014
0.016
0.022
0.018
0.022
0.024
0.027
0.029
0.020
0.020
0.020
0.021

0.0767
0.0918
0.0357
0.0337
0.0482
0.0406
0.0188
0.0149
0.0207
0.0244
13.90
0.0140
0.0149
0.0216
0.0178
0.0149
0.0168
0.0226
0.0188
0.0226
0.0244
0.0273
0.0292
0.0207
0.0207
0.0207
0.0216

5.93
6.24
9.45
9.45
9.38
8.39
15.11
9.18
12.79
14.12
126.15
12.65
11.85
12.25
12.02
11.05
10.97
10.97
11.07
. 10.71
10.75
10.68
10.79
10.77
10.80
10.78
10.69

1.293
1.472
0.377
0.356
0.513
0.484
0.124
0.163
0.162
0.173
11.02

0.111
0.126
0.176
0.148
0.135
0.153
0.206
0.169
0.211
0.227
0.256
0.270
0.192
0.191
0.192
0.202

+Samples diluted to 100 ml prior to absorbence measurement.
•Sample diluted to 1000 ml prior to absorbence measurement.

W T % E L EM EN T A L PHOSPHORUS LE A C H IN G D A TA

Sample
ID
UMR-3

Time
(days)
7
15

Absorbence at
400 nm
0.024
0.044

Wt of
Phosphorus (mg)
Calculated
Initially
in Solution in Glass
0.0244
0.0434

4.76
6.00

Wt %
Phosphorus
Leached
0.513
0.724

EX A M PLE 2
65

The glass compositions listed in Table VI were pre
pared from reagent grade materials. Batches o f 25 or 50
grams were melted in platinum crucibles in an electric
furnace at 1500 to 1600° C. A period o f 2 to 3 hours at
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temperature was allowed for fining and homogenization
o f the melt. The glasses were cast into bars measuring
approximately 1 x 1 x 6 cm in steel molds and were
annealed at approximately 800° C. for 8 to 12 hours.
Excess glass in the crucibles was quenched in water,
broken from the crucible, and saved for spheroidizing.
Spheroidization o f each o f the glasses into microspheres
was performed according to the procedures o f Example
1. Table VI also lists the density, pouring temperature
and appearance for each o f the glasses identified.
The glass compositions listed in Table VI were also
evaluated for chemical durability with the results being
provided in Table VII. Table V II provides the dissolu
tion rate for YAS glass samples 2-8 and for vitreous
silica as determined in IN HC1 under the conditions
specified.
FIG. 4 reports the percent radioactive yttrium
leached from sample YAS-1 over time and under the
conditions expressed in Table VII. Each point in FIG. 4
represents the amount o f radiation measured in solution
divided by the initial Y-90 activity, the ratio being ex
pressed as a percent. When expressed in this manner, it
is apparent that the amount o f Y-90 leached from the
microsphere is well within the acceptability limit.
In FIG. 5, each point represents the measured activ
ity o f leachate from sample YAS-1 over time and under
the conditions expressed in Table VII. A lso presented
on this plot is a line representing the half-life o f Y-90.
The high degree o f correlation between the points and
this line demonstrate that there was not a significant
amount o f any radioisotope other than Y-90 leached
from sample YAS-1.

T A B L E VH-continued

5

Glass
S i0 2

D ISSO LU TIO N R A TES IN IN HCI OF
YAS G LA SSES A N D V ITREO US SILICA
Dissolution Rate (g/cm 23456min)
6 days @ 50° C.
15 days @ 30° C.
7 days
5.0 X 10~8

@ 50° C.

5.5 X 10“ 9

In view o f the above, it w ill be seen that the several
10 objects o f the invention are achieved and other advanta
geous results attained.
A s various changes could be made in the above meth
ods and products, without departing from the scope of
the invention, it is intended that all matter contained in
15 the above description or shown in the accompanying
drawings shall be interpreted as illustrative and not in a
limiting sense.
What is claimed is:
1. A glass microsphere having a diameter o f about 75
20 micrometers or less and adapted for radiation therapy of
a mammal, said glass consisting essentially o f an yttrium
oxide-aluminosilicate glass composition lying substan
tially within a quadrilateral region o f the ternary com 
position diagram o f the yttria-alumina-silica system, the
25 quadrilateral region being defined by its four corners
having the following combination o f weight propor
tions o f the components: 20% silica, 10% alumina, 70%
yttria; 70% silica, 10% alumina, 20% yttria; 70% silica,
20% alumina, 10% yttria; and 20% silica, 45% alumina,
30 35% yttria, the glass having a chemical durability such
that subsequent to irradiation and administration o f the
microsphere to the mammal, the microsphere will not

TABLE VI
Sample
YAS-1
YAS-2
YAS-3
YAS-4
YAS-5
YAS-6
YAS-7
YAS-8
YAS-9
YAS-10

Composition (wt %)
Y 2O 3 AI2O 3 S i0 2

33
55

21
20

50
40
25
42
40
40
55
35

20
20
20
25
30
13
15
35

46
55
30
40
55
33
30
47
30
30

Density
Gm/cm^

Pouring
Temp, “C.

3.07
3.81
3.65
3.29
2.84
3.42
3.39
3.23
3.81
3.30

1500
1550
1550
1500
1600
1500
1500
1600
1600
1600

Appearance
Viscous, Clear Glass
Fluid
Fluid, Clear Glass
Fluid, Clear Glass
Viscous, Opal Glass
Fluid, Clear Glass
Fluid, Clear Glass
Fluid, Opal Glass
Fluid, Clear Glass
Fluid, Clear Glass

TA B L E VII

Glass
YAS-2
3
4
5
6
7
8

D ISSO LU TIO N R A TES IN IN HC1 O F
YAS G LA SSES A N D V ITREO US SILIC A
______________ Dissolution Rate (g/cnA nin)____________
6 days @ 50° C.
15 days @ 30° C.
7 days @ 50* C.
54.6 X 10~7
36.2 X 1 0 - 7
7.8 X 1 0 - 7
3.4 X 10“ 7
28.1 X 10“ 7
28.3 X 1 0 - 7
7.2 X 1 0 - 7

2.8 X 10“ 7

2.1 X 10“ 7

5.7 X 10“ 7
3.9 X 1 0 -7

6.8 X lO -7
2.8 X 10“ 7

release a significant amount o f yttrium-90 into the mam
mal’s system.
2. A glass microsphere as set forth in claim 1 wherein
said microsphere is substantially spherical having a
50 smooth surface.
3. A glass microsphere as set forth in claim 1 wherein
said diameter is between about 5 and about 75 microme
ters.
4. A glass microsphere as set forth in claim 1 wherein
5 said diameter is between about 20 and about 30 microm
eters.
5. A glass microsphere as set forth in claim 1 wherein
said microsphere is essentially void-free.
6. A glass microsphere as set forth in claim 1 wherein
u said microsphere has a hollow core.
7. A glass microsphere as set forth in claim 1 wherein
said microsphere has a plurality o f hollow cells.
8. A glass microsphere as set forth in claim 1 wherein
said glass remains durable following neutron irradiation
with an intense thermal neutron flux.
* * * * *

